Minimally invasive parathyroid carcinoma-A missing entity between parathyroid adenoma and carcinoma: Scintigraphic and histological features.


Journal

Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653

Informations de publication

Date de publication:
12 2019
Historique:
received: 12 06 2019
revised: 21 08 2019
accepted: 28 08 2019
pubmed: 4 9 2019
medline: 15 9 2020
entrez: 4 9 2019
Statut: ppublish

Résumé

Minimally invasive parathyroid carcinoma (MIPC) is clinically and biochemically comparable with parathyroid adenoma (PA) though histopathologically differ from PA. MIPC is an intermediate of PA and parathyroid carcinoma (PC). In literature, there is no definite criterion to diagnose MIPC. Our aim was to evaluate and characterize the imaging and biochemical parameters with histological characteristics of MIPC. Ten patients with MIPC were recruited from (single centre) Indian PHPT registry (www.indianphptregistry.com) from January 2014 to July 2018. Clinical, biochemical, imaging and histological features of MIPC patients were reviewed. The mean age of MIPC patients (n = 10; 3 males) was 39.9 ± 11.3 years (range: 17-50). All patients had an elevated preoperative parathyroid hormone (iPTH) level ranging from 427 to 2138 pg/mL (median: 1328). MIBI scan showed intensely avid and enlarged parathyroid tumours in all patients; LIPT in 6, RIPT in 3 and ectopic mediastinal in 1 with mean size of the tumours was 2.8 ± 1.1 cm. The mean of maximum standardized uptake value (SUVmax) of MIPC in F-18 fluorocholine PET/CT was 6.7 ± 1.1 (range 6.0-8.3). The mean tumour weight was 12 ± 9.5 g (range: 1.09-28). All MIPC patients had identified capsular invasion in 80% and vascular invasion in 50% only but there was no local invasion, lymph nodal or distant metastasis. The mean Ki-67 labelling index was 3.2 ± 2.7 (range 1.1-10). The study concluded that MIPC patients are less aggressive (on the basis of imaging and histopathological findings) and should be differentiated from parathyroid adenoma and carcinoma.

Identifiants

pubmed: 31479153
doi: 10.1111/cen.14088
doi:

Substances chimiques

Technetium Tc 99m Sestamibi 971Z4W1S09

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

842-850

Informations de copyright

© 2019 John Wiley & Sons Ltd.

Références

Pallan S, Khan A. Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care. Can Fam Physician. 2011;57:184-189.
Bhadada SK, Arya AK, Mukhopadhyay S, et al. Primary hyperparathyroidism: insights from the Indian PHPT registry. J Bone Miner Metab. 2018;36:238-245.
Kebebew E, Clark OH. Parathyroid adenoma, hyperplasia, and carcinoma: localization, technical details of primary neck exploration, and treatment of hypercalcemic crisis. Surg Oncol Clin N Am. 1998;7:721-748.
Krishna Mohan VS, Narayan ML, Mukka A, et al. Atypical parathyroid adenoma with multiple brown tumors as initial presentation: a rare entity. Indian J Nucl Med. 2017;32:133-136.
Pyo JS, Cho WJ. Diagnostic and prognostic implications of parafibromin immunohistochemistry in parathyroid carcinomaT. Biosci Rep. 2019;39.
Johnson SJ. Changing clinicopathological practice in parathyroid disease. Histopathology. 2010;56:835-851.
Chang YJ, Mittal V, Remine S, et al. Correlation between clinical and histological findings in parathyroid tumors suspicious for carcinoma. Am Surg. 2006;72:419-426.
Bhargav PR. Typifying the atypical parathyroid adenoma. Indian J Nucl Med. 2017;32:255.
Kameyama K, Takami H. Proposal for the histological classification of parathyroid carcinoma. Endocr Pathol. 2005;16:49-52.
Truran PP, Johnson SJ, Bliss RD, Lennard TW, Aspinall SR. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg. 2014;38:2845-2854.
Ippolito G, Palazzo FF, Sebag F, De Micco C, Henry JF. Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. British J Surg. 2007;94:566-570.
Lezaic L, Rep S, Sever MJ, Kocjan T, Hocevar M, Fettich J. (1)(8)F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging. 2014;41:2083-2089.
Michaud L, Balogova S, Burgess A, et al. A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine. 2015;94: e1701.
Thanseer N, Bhadada SK, Sood A, et al. Comparative effectiveness of ultrasonography, 99mTc-Sestamibi, and 18F-Fluorocholine PET/CT in detecting parathyroid adenomas in patients with primary hyperparathyroidism. Clin Nucl Med. 2017;42:e491-e497.
Schweighofer-Zwink G, Hehenwarter L, Rendl G, et al. Imaging of parathyroid adenomas with F18 choline PET-CT. Wien Med Wochenschr. 2019;169:15-24.
Misiorowski W, Czajka-Oraniec I, Kochman M, Zgliczynski W, Bilezikian JP. Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidism. Endocrine. 2017;58:380-385.
Syed Z, Khan A. Skeletal effects of primary hyperparathyroidism. Endocr Pract. 2000;6:385-388.
Bhanu Murthy R, Srihari V, Lakshmi Narayana M. Parathyroid adenoma in a young male with multiple fractures and varied clinical features. Indian J Otolaryngol Head Neck Surg. 2014;66:114-117.
Tkachenko R, Zakhartseva L, Golovko A, Kuryk O, Lazarenko G. Parathyroid carcinoma: a case report. Exp Oncol. 2019;41:72-75.
Quaglino F, Marchese V, Lemini R, et al. Parathyroid carcinoma. A single Institution experience and a review of the international literature. Ann Ital Chir. 2018;89:295-304.
Agarwal G, Prasad KK, Kar DK, Krishnani N, Pandey R, Mishra SK. Indian primary hyperparathyroidism patients with parathyroid carcinoma do not differ in clinicoinvestigative characteristics from those with benign parathyroid pathology. World J Surg. 2006;30:732-742.
Stern S, Mizrachi A, Strenov Y, et al. Parathyroid adenoma: a comprehensive biochemical and histological correlative study. Clin Otolaryngol. 2017;42:381-386.
Pradeep PV, Jayashree B, Mishra A, Mishra SK. Systematic review of primary hyperparathyroidism in India: the past, present, and the future trends. Int J Endocrinol. 2011;2011:921814.
Shah VN, Bhadada SK, Bhansali A, et al. Effect of gender, biochemical parameters & parathyroid surgery on gastrointestinal manifestations of symptomatic primary hyperparathyroidism. Indian J Med Res. 2014;139:279-284.
Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer. 1973;31:600-605.
Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol. 1993;17:820-829.
Sobrinho-Simoes M, Eloy C, Magalhaes J, Lobo C, Amaro T. Follicular thyroid carcinoma. Mod Pathol. 2011;24(Suppl 2):S10-18.
Pradhan R, Agarwal A. Prognostic impact of further treatments on distant metastasis in patients with minimally invasive follicular thyroid carcinoma: verification using inverse probability of treatment weighting. World J Surg. 2017;41:1143.
Robinson A, Schneider D, Sippel R, Chen H. Minimally invasive follicular thyroid cancer: treat as a benign or malignant lesion? J Surg Res. 2017;207:235-240.
Kumari N, Chaudhary N, Pradhan R, Agarwal A, Krishnani N. Role of histological criteria and immunohistochemical markers in predicting risk of malignancy in parathyroid neoplasms. Endocr Pathol. 2016;27:87-96.
Givi B, Shah JP. Parathyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22:498-507.
Sharretts JM, Kebebew E, Simonds WF. Parathyroid cancer. Semin Oncol. 2010;37:580-590.
Dionisi S, Minisola S, Pepe J, et al. Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. Mayo Clin Proc. 2002;77:866-869.

Auteurs

Priyanka Singh (P)

Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Shelvin Kumar Vadi (SK)

Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Uma Nahar Saikia (UN)

Department of Histopathology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Ashwani Sood (A)

Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Divya Dahiya (D)

Department of General Surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Ashutosh Kumar Arya (AK)

Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Arunanshu Behera (A)

Department of General Surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Soham Mukherjee (S)

Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Sapara Mohin Arvindkumar (SM)

Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Sanjay Kumar Bhadada (SK)

Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH